These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 23534873)
21. The Effect of CpG Sequences on Capsid-Specific CD8 Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483 [TBL] [Abstract][Full Text] [Related]
22. Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo. Gabriel N; Hareendran S; Sen D; Gadkari RA; Sudha G; Selot R; Hussain M; Dhaksnamoorthy R; Samuel R; Srinivasan N; Srivastava A; Jayandharan GR Hum Gene Ther Methods; 2013 Apr; 24(2):80-93. PubMed ID: 23379478 [TBL] [Abstract][Full Text] [Related]
23. AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating. Tenney RM; Bell CL; Wilson JM Virology; 2014 Apr; 454-455():227-36. PubMed ID: 24725949 [TBL] [Abstract][Full Text] [Related]
24. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Chen J; Wu Q; Yang P; Hsu HC; Mountz JD Mol Ther; 2006 Feb; 13(2):260-9. PubMed ID: 16324888 [TBL] [Abstract][Full Text] [Related]
25. Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33. Mays LE; Wang L; Tenney R; Bell P; Nam HJ; Lin J; Gurda B; Van Vliet K; Mikals K; Agbandje-McKenna M; Wilson JM J Virol; 2013 Sep; 87(17):9473-85. PubMed ID: 23720715 [TBL] [Abstract][Full Text] [Related]
26. Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Rossi A; Dupaty L; Aillot L; Zhang L; Gallien C; Hallek M; Odenthal M; Adriouch S; Salvetti A; Büning H Sci Rep; 2019 Mar; 9(1):3631. PubMed ID: 30842485 [TBL] [Abstract][Full Text] [Related]
27. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425 [TBL] [Abstract][Full Text] [Related]
28. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Hauck B; Murphy SL; Smith PH; Qu G; Liu X; Zelenaia O; Mingozzi F; Sommer JM; High KA; Wright JF Mol Ther; 2009 Jan; 17(1):144-52. PubMed ID: 18941440 [TBL] [Abstract][Full Text] [Related]
29. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. Raupp C; Naumer M; Müller OJ; Gurda BL; Agbandje-McKenna M; Kleinschmidt JA J Virol; 2012 Sep; 86(17):9396-408. PubMed ID: 22718833 [TBL] [Abstract][Full Text] [Related]
30. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid. Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388 [TBL] [Abstract][Full Text] [Related]